A. Duca

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis

J. Kane, R. Mcquade, R. Baker, 2015, Journal of medical economics.

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study

R. Mcquade, R. Baker, T. Peters-Strickland, 2015, npj Schizophrenia.

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.

F. Tacke, F. Koenig, E. Meyer, 2022, Journal of hepatology.

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Xiang Li, R. Shelton, M. Trivedi, 2019, JAMA psychiatry.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

J. Kane, R. Mcquade, R. Baker, 2013, Journal of medical economics.